Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUKE WEBB

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1932161916
CMS profile
314032
Location
COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$18,672.96

96 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUKE WEBB

NPI 1932161916 · CMS profile ID 314032

Allopathic & Osteopathic Physicians / Internal Medicine

COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932161916?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932161916?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932161916?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LUKE WEBB, NPI 1932161916, CMS profile ID 314032, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932161916?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

96 matching records · $18,672.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 96 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–96 of 96.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $6.7107/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369260 CMS
GENZYME CORPORATION $15.7507/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369258 CMS
Teva Pharmaceuticals USA, Inc. $18.0307/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247443479 CMS
Grifols USA, LLC $15.6306/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249535179 CMS
Regeneron Healthcare Solutions, Inc. $17.4506/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213068396 CMS
AstraZeneca Pharmaceuticals LP $2,800.0006/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206725431 CMS
AstraZeneca Pharmaceuticals LP $1,850.0006/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207201676 CMS
GENZYME CORPORATION $15.7806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369262 CMS
AstraZeneca Pharmaceuticals LP $20.5606/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206218732 CMS
AstraZeneca Pharmaceuticals LP $124.4106/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206373845 CMS
PFIZER INC. $20.2806/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228901885 CMS
AstraZeneca Pharmaceuticals LP $115.4306/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206722542 CMS
GENZYME CORPORATION $20.5006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369228 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.4706/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223914620 CMS
Novartis Pharmaceuticals Corporation $21.1605/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200519680 CMS
AstraZeneca Pharmaceuticals LP $450.0005/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206688383 CMS
AstraZeneca Pharmaceuticals LP $1,850.0005/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206441282 CMS
AstraZeneca Pharmaceuticals LP $34.8305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206616585 CMS
AstraZeneca Pharmaceuticals LP $32.9005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206711093 CMS
GENZYME CORPORATION $29.4805/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369208 CMS
Pharming Healthcare, Inc. $26.3805/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200804300 CMS
GENZYME CORPORATION $21.5604/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369182 CMS
ARS Pharmaceuticals Operations, Inc. $24.6504/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245896779 CMS
PFIZER INC. $17.7504/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228824872 CMS
AstraZeneca Pharmaceuticals LP $125.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206635900 CMS
AstraZeneca Pharmaceuticals LP $100.0004/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207192031 CMS
AstraZeneca Pharmaceuticals LP $250.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206403781 CMS
Regeneron Healthcare Solutions, Inc. $21.8003/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213068394 CMS
Grifols USA, LLC $23.4203/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249535183 CMS
AstraZeneca Pharmaceuticals LP $90.0903/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206550008 CMS
AstraZeneca Pharmaceuticals LP $85.9102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207031233 CMS
Pharming Healthcare, Inc. $18.4702/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200804298 CMS
Regeneron Healthcare Solutions, Inc. $20.6502/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213068392 CMS
AstraZeneca Pharmaceuticals LP $1,850.0002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206459155 CMS
AstraZeneca Pharmaceuticals LP $19.3602/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206576613 CMS
AstraZeneca Pharmaceuticals LP $450.0002/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206684436 CMS
AstraZeneca Pharmaceuticals LP $76.0802/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206313984 CMS
GlaxoSmithKline, LLC. $14.4202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190758550 CMS
AstraZeneca Pharmaceuticals LP $16.0402/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206644905 CMS
CSL Behring $23.6002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232363841 CMS
PFIZER INC. $16.5502/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231220312 CMS
Grifols USA, LLC $15.2601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249535188 CMS
GENZYME CORPORATION $10.9701/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369160 CMS
GlaxoSmithKline, LLC. $17.3801/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191823369 CMS
Phadia US Inc. $21.6601/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1161496346 CMS
PFIZER INC. $17.0701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231109785 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,637.68 101
PY2020 $6,301.54 56
PY2021 $23,392.42 103
PY2022 $69,181.85 161
PY2023 $57,423.17 124
PY2024 $65,677.45 161
PY2025 $18,672.96 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $494,431.12 30
PY2024 Principal investigator $118,299.84 32
PY2023 Principal investigator $180,488.28 45
PY2022 Principal investigator $345,323.67 36
PY2021 Principal investigator $207,586.30 26
PY2020 Principal investigator $232,727.42 42
PY2019 Principal investigator $196,413.48 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,459.52 12/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045894
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,703.66 11/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046154
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $61,864.56 11/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046152
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185525
Principal investigator 1 GlaxoSmithKline, LLC. $2,305.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185529
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,631.78 10/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046150
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,765.64 10/14/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046148
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $741.00 10/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046146
Principal investigator 1 AstraZeneca UK Limited $33,536.00 09/26/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185537655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 09/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046270
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,748.56 09/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046144
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,647.72 09/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046142
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,130.70 08/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046140
Principal investigator 1 GlaxoSmithKline, LLC. $19,300.00 08/01/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185532
Principal investigator 1 GlaxoSmithKline, LLC. $2,788.00 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187103
Principal investigator 1 GlaxoSmithKline, LLC. $17,019.90 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,748.51 07/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046138
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045850
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,861.51 06/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046136
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,763.57 05/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046336
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,285.14 04/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046334
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046056
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,243.89 03/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046332
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,246.53 03/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046330
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046054
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,727.35 02/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046328
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,028.33 01/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046326
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,040.72 01/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046324
Principal investigator 1 Eli Lilly and Company $172,384.33 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187880645